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Summary
 
Mitogen-activated protein (MAP) kinase family members, including extracellular signal–regu-
lated kinase (ERK), c-Jun NH
 
2
 
-terminal kinase (JNK), and p38 MAP kinase, have been impli-
cated in coupling the B cell antigen receptor (BCR) to transcriptional responses. However, the
mechanisms that lead to the activation of these MAP kinase family members have been poorly
elucidated. Here we demonstrate that the BCR-induced ERK activation is reduced by loss of
Grb2 or expression of a dominant-negative form of Ras, RasN17, whereas this response is not
affected by loss of Shc. The inhibition of the ERK response was also observed in phospholipase
C (PLC)-
 
g
 
2–deficient DT40 B cells, and expression of RasN17 in the PLC-
 
g
 
2–deficient cells
completely abrogated the ERK activation. The PLC-
 
g
 
2 dependency of ERK activation was
most likely due to protein kinase C (PKC) activation rather than calcium mobilization, since
loss of inositol 1,4,5-trisphosphate receptors did not affect ERK activation. Similar to coopera-
tion of Ras with PKC activation in ERK response, both PLC-
 
g
 
2–dependent signal and GTP-
ase are required for BCR-induced JNK and p38 responses. JNK response is dependent on
Rac1 and calcium mobilization, whereas p38 response requires Rac1 and PKC activation.
Key words: mitogen-activated protein kinase family • Ras • Rac1 • protein kinase C • 
calcium
 
T
 
he B cell antigen receptor (BCR)
 
1
 
 complex has im-
portant functions in the binding and internalization of
antigen as well as in transducing signals through the plasma
membrane that lead to cell activation, proliferation, and apop-
tosis. One immediate consequence of triggering the BCR is
the activation of protein tyrosine kinases and the resulting
induction of phospholipase C (PLC)-
 
g
 
2–mediated hydro-
lysis of inositol phospholipids to generate diacylglycerol and
inositol 1,4,5-trisphosphate (IP
 
3
 
), which induce protein ki-
nase C (PKC) activation and elevate intracellular calcium
([Ca
 
2
 
1
 
]
 
i
 
), respectively (1–4). Supporting these sequential
events, PLC-
 
g
 
2–deficient DT40 B cells exhibit neither
PKC activation nor calcium mobilization after BCR liga-
tion (5), whereas the PKC activation still occurs in IP
 
3
 
 re-
ceptor (IP
 
3
 
R)-deficient DT40 cells (6). Thus, combined
analyses using PLC-
 
g
 
2– and IP
 
3
 
R-deficient DT40 cells
have allowed us to dissect the requirement of PKC and cal-
cium mobilization in BCR-mediated signaling pathways.
BCR stimulation also leads to extracellular signal–regu-
lated kinase (ERK) activation, which in turn activates tran-
scription factors (7–11). Analogous to receptor tyrosine ki-
nases, the interaction of Grb2, Shc, and Sos, which have
been implicated in the activation of Ras, is thought to be a
potential pathway for the activation of ERK after BCR li-
gation (12–14). In addition to this potential pathway, there
is evidence that the ERK cascade is activated by treatment
with PMA and ionomycin in cultured 3T3 fibroblasts (15).
However, it is not known whether BCR-induced ERK
activation requires PKC activation and/or [Ca
 
2
 
1
 
]
 
i
 
 increase.
Moreover, there is no direct evidence for the involvement
of Grb2, Shc, and Ras in BCR-induced ERK activation.
In addition to ERK, other mitogen-activated protein
 
1
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2
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Activation of MAP Kinase Family Members by PLC-
 
g
 
2 and GTPases
 
(MAP) kinase family members c-Jun NH
 
2
 
-terminal kinase
(JNK) and p38 are known to be stimulated by BCR cross-
linking, although less effectively than is ERK (11, 16, 17).
In a fibroblast cotransfection system, Rac1 has been shown
to stimulate JNK and p38 (18–20). Furthermore, recent
experiments have demonstrated that Vav, upon tyrosine
phosphorylation, can activate members of the Rho family
of GTPases (21–23). Although these observations provide
the intriguing possibility that the activated Rac1 by Vav
leads to activation of JNK and p38, any link between
BCR-regulated Rac1 and the activation of JNK and p38
has not yet been explored.
Different activation patterns of these MAP kinase family
members (ERK, JNK, p38) may lead to differential expres-
sion of genes and contrasting cellular phenotypes, such as
growth or apoptosis in B cells. This concept is supported
by the evidence obtained from the cultured B cell system
and the anti–hen egg lysozyme transgenic mice system. Us-
ing the human B lymphoma cell line, B104, it has been
suggested that JNK and p38, not ERK, are involved in
membrane IgM-induced apoptosis (16). Moreover, in trans-
genic mice, both ERK and JNK are activated by foreign
antigen in naive B cells, whereas ERK, but not JNK, is
activated by self-antigen in tolerant B cells (24).
In this study, we focus upon how BCR activates ERK,
JNK, and p38. RasN17 inhibited the BCR-induced ERK
activation without affecting JNK and p38 responses. Con-
versely, the JNK and p38 responses were abrogated by ex-
pression of a dominant-negative form of Rac1 and Rac1N17,
but not of RasN17. In addition to demonstrating require-
ment of these GTPases, our results reveal the importance of
the PLC-
 
g
 
2 pathway in activation of these MAP kinase
family members.
 
Materials and Methods
 
Cells, Expression Constructs, and Antibodies.
 
Wild-type and var-
ious mutant DT40 cells were cultured in RPMI 1640 supple-
mented with 10% FCS, 1% chicken serum, 50 
 
m
 
M 2-ME, 2 mM
 
l
 
-glutamine, and antibiotics. The cDNA of RasN17 (provided by
T. Urano, Department of Biochemistry, Nagoya University
School of Medicine, Nagoya, Japan) and Myc-tagged Rac1N17
(reference 25; provided by G. Bokoch, Department of Immunol-
ogy and Cell Biology, Scripps Research Institute, La Jolla, CA)
were cloned into expression vector pApuro (26). These cDNAs
were transfected by electroporation at 550 V, 25 
 
m
 
F, and selected
in the presence of 0.5 
 
m
 
g/ml puromycin (Sigma Chemical Co.,
St. Louis, MO). Expression of transfected cDNA was confirmed
by Western blot analysis. The mAb used for the stimulation of
BCR was M4, which recognizes chicken IgM (27). Anti-Grap Ab
were obtained by immunizing rabbits with bacterially expressed
glutathione 
 
S
 
-transferase (GST) fusion protein containing chicken
Grap SH2 domain. The following Abs were purchased: anti-
ERK2 and anti-p38 from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA); anti-JNK1 and anti-Myc from PharMingen (San Di-
ego, CA); anti-Grb2 Ab from Transduction Labs., Inc. (Lexing-
ton, KY); anti-Shc from Upstate Biotechnology, Inc. (Lake
Placid, NY); and anti-Ras from Oncogene (Cambridge, MA).
 
Generation of Various Deficient DT40 Cells.
 
Based on published
sequence of Grap (28) and Shc (29), each chicken cDNA was
cloned by reverse transcriptase-PCR method using RNA from
DT40 B cells. Chicken Grb2 cDNA sequence has already been
published (30). Genomic clones of Grb2, Grap, and Shc were ob-
tained by PCR using oligonucleotides designed from each cDNA
sequence and genomic DNA as a template. The targeting vectors,
pGrb2-neo and pGrb2-hisD, were constructed by replacing the
genomic fragment containing exons that correspond to chicken
Grb2 SH2 domain, amino acid residues 59–166 (30), with neo
and hisD cassettes. These cassettes were flanked by 2.3 and 1.8 kb
of Grb2 sequence on the 5
 
9
 
 and 3
 
9
 
 sides, respectively. Selection
was done in the presence of G418 (2 mg/ml) and clones were
screened by Southern blot analysis. The pGrb2–hisD was again
transfected into the neo-targeted clone and selected with both
G418 (2 mg/ml) and histidiol (1 mg/ml). Introduction of a single
copy of each targeting vector was verified by reprobing the blots
with internal neo or hisD probe. The bsr and bleo targeting con-
structs of Grap were made by replacing the genomic fragment
containing exons corresponding to human Grap SH2 domain,
amino acid residues 59–100 (28), with bsr and bleo cassettes.
These constructs spanned 0.8 (5
 
9
 
 side) and 1.2 kb (3
 
9
 
 side) of
Grap sequence. They were sequentially transfected into DT40
cells by electroporation to obtain a null mutant. Selection for
drug-resistant clones was carried out by using blastcidin S (50 
 
m
 
g/ml)
and phleomycin (0.3 mg/ml). The constructs (pShc–neo and
pShc–hisD) were designed for neo and hisD cassettes to replace
exons that correspond to human Shc amino acid residues 101–
140 (29). The neo and hisD cassettes were flanked by 0.9 and 1.3
kb of Shc sequence on the 5
 
9
 
 and 3
 
9
 
 sides, respectively. Selection
was performed as described above for Grb2. In this study, we also
used DT40 cells deficient in PLC-
 
g
 
2 and all three isoforms of
IP
 
3
 
R, all of which have been described previously (5, 6).
 
Northern Blot Analysis.
 
RNA was prepared from wild-type
and mutant DT40 cells using the guanidium thiocyanate method.
Total RNA (20 
 
m
 
g) was separated in a 1.2% formaldehyde gel,
transferred to Hybond-N
 
1
 
 nylon membrane (Nycomed Amer-
sham, Arlington Heights, IL), and probed with 
 
32
 
P-labeled cDNAs.
 
Western Blot Analysis.
 
Wild-type, Grb2-, Grap-, and Shc-defi-
cient cell lysates were separated by SDS-PAGE gel, transferred to
nitrocellulose membrane, and detected by appropriate Abs and
the ECL system (Nycomed Amersham).
 
In Vitro Kinase Assay.
 
After incubation with the indicated
stimuli, 2–5 
 
3 
 
10
 
6 
 
cells were lysed in 500 
 
m
 
l of lysis buffer (50
mM Tris-Cl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 2% Triton
X-100, 100 
 
m
 
M sodium vanadate, 10 mM sodium pyrophosphate,
2 mM PMSF, 10 
 
m
 
g/
 
m
 
l leupeptin, and 2 
 
m
 
g/
 
m
 
l aprotinin) for 30
min on ice. Cell debris were removed by centrifugation at 16,000 
 
g
 
for 15 min at 4
 
8
 
C. Precleared lysates were immunoprecipitated by
1 
 
m
 
g anti-ERK2 Ab, 1 
 
m
 
g anti-JNK1 Ab, or 1 
 
m
 
g anti-p38 Ab
with 40 
 
m
 
l protein G–Sepharose (Amersham Pharmacia Biotech,
Piscataway, NJ). The beads were pelleted by centrifugation and
then washed three times with lysis buffer, two times with washing
buffer (50 mM Hepes, pH 7.4, 10 mM MgCl
 
2
 
, 100 
 
m
 
M sodium
vanadate, and 2 mM dithiothreitol). Immunoprecipitates were di-
vided and half of them were used for Western blot analysis. The
remaining half were washed once with kinase assay buffer (20 mM
Hepes, pH 7.4, 10 mM MgCl
 
2
 
, 10 mM MnCl
 
2
 
, 2 mM dithiothre-
itol, and 10 
 
m
 
M sodium vanadate). Immune complexes were sus-
pended in 30 
 
m
 
l kinase assay buffer containing 
 
g
 
-[
 
32
 
P]ATP
(
 
.
 
3,000 Ci/mmol; NEN
 
Ô
 
 Life Science Products, Boston, MA)
and 5 
 
m
 
M cold ATP. 5 
 
m
 
g of GST–Elk, GST–c-Jun (provided by
M. Hibi, Biomedical Research Center, Osaka University Medical
School, Suita, Japan) and GST–ATF2 fusion protein were added
as substrates for ERK2, JNK, and p38, respectively. After 20 min 
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of incubation at 30
 
8
 
C, the reaction was terminated by the addi-
tion of SDS sample buffer followed by boiling for 5 min. The
samples were separated by SDS-PAGE gel, dried, and subjected
to autoradiography.
 
Results
 
Requirement for Grb2, not Shc, in BCR-mediated ERK Acti-
vation.
 
To determine the necessity or redundancy of
Grb2 and Shc in the BCR-induced ERK activation, we
generated DT40 B cells deficient in these molecules by the
gene targeting method. Since Grap has recently been
shown to possess similar structural characteristics to Grb2
and this protein is prominently expressed in lymphoid cells
(28, 31), we also established Grap-deficient DT40 cells.
Lack of Grb2, Grap, and Shc was verified by Northern and
Western blot analyses (Fig. 1, 
 
A
 
 and 
 
B
 
). The level of cell
surface expression of BCR on these targeted DT40 cells
was the same as that of parental DT40 cells (data not
shown).
RNA analysis by reverse transcriptase-PCR method and
Western blot analysis (32) indicated that ERK2 is the pre-
dominant isoform expressed in DT40 B cells. After BCR
stimulation, DT40 cells were lysed and immunoprecipi-
tated with anti-ERK2 Ab. The immunoprecipitates were
assayed for its in vitro kinase activity by the ability to phos-
phorylate the substrate Elk-1. This anti-ERK2 Ab does not
recognize JNK or p38 (Fig. 2). Consistent with previous
reports (9, 10, 33, 34), activation of ERK2 in DT40 cells
was maximal at 1 and 3 min, after which activity declined
to a lower level (Figs. 3 and 4). Compared with wild-type
cells, the BCR-induced ERK2 response was reduced ap-
proximately twofold by loss of Grb2. However, the ERK2
response was not reduced in Shc-deficient DT40 cells (Fig.
3), demonstrating that Grb2, but not Shc, is required for
the BCR-induced ERK2 activation. Moreover, despite the
structural similarity between Grb2 and Grap, Grap-defi-
cient DT40 B cells exhibited no decrease in BCR-medi-
ated ERK2 activation (Fig. 3), implicating that Grb2 and
Grap have distinct function(s) in BCR signaling.
Since Grb2 is essential for Ras activation in receptor-
type tyrosine kinase signaling, we decided to test whether
Grb2 is involved in the ERK2 response along a Ras-depen-
dent pathway in BCR signaling. As shown in Fig. 5, ex-
pression of RasN17 (Fig. 1 
 
C
 
) inhibited ERK2 activation
by threefold compared with wild-type cells, suggesting that
Ras activation, perhaps via Grb2, is required for BCR-
induced ERK2 activation. The residual ERK2 response by
loss of Grb2 or expression of RasN17 implicates that an ad-
ditional signal(s) is required for the maximum ERK2 acti-
vation and that this additional signal is able to stimulate
ERK2 to some extent even in the absence of Ras activation.
 
Both PKC and Ras Pathways Are Required for ERK Activa-
tion.
 
Recent work has implicated PKC and/or [Ca
 
2
 
1
 
]
 
i
 
 in-
crease as a cofactor for ERK activation (7, 15). To deter-
mine whether PKC and [Ca
 
2
 
1
 
]
 
i
 
 increase are required for
BCR-induced ERK activation, we used PLC-
 
g
 
2– and
IP
 
3
 
R-deficient DT40 cells. We have previously shown that
the BCR-induced [Ca
 
2
 
1
 
]
 
i
 
 increase is completely abrogated
in both PLC-
 
g
 
2– and IP
 
3
 
R-deficient DT40 cells, whereas
PKC activation is abolished only in PLC-
 
g
 
2–deficient cells
(6). BCR ligation stimulated ERK2 activation even in the
IP
 
3
 
R-deficient cells, whereas this activation was markedly
inhibited by loss of PLC-
 
g
 
2 (Fig. 3). These data suggest
that the PKC pathway rather than the calcium pathway is
required for the BCR-induced ERK2 activation. Further-
more, the extent of the inhibition by loss of PLC-
 
g
 
2 was
more than that in DT40 cells expressing RasN17 (Fig. 5),
suggesting that the PKC pathway may play a more domi-
nant role than Ras in BCR-mediated ERK2 activation.
The residual ERK2 activation in PLC-
 
g
 
2–deficient
DT40 cells was completely abolished by expression of
Figure 1. Disruption of Grb2, Grap, and Shc genes in DT40 cells. (A)
RNA expression of Grb2, Grap, and Shc was analyzed by Northern blot
analysis using each chicken cDNA probe (top) or b-actin (bottom) (refer-
ence 64). Positions of 28S and 18S RNA are shown. (B) Grb2, Grap, and
Shc protein expression in wild-type and targeted DT40 cells. Each pro-
tein was detected by Western blotting analysis using anti-Grb2, anti-Grap,
and anti-Shc Abs. (C) Expression of dominant-negative Ras and domi-
nant-negative Rac1.1290 Activation of MAP Kinase Family Members by PLC-g2 and GTPases
RasN17 in this mutant DT40 cell (Fig. 5). Together, these
data suggest that Ras activation and the PKC-dependent
pathway may work synergistically for the maximum BCR-
induced ERK2 activation.
Requirement for Rac1 in BCR-induced JNK and p38 Activa-
tion. After BCR stimulation, the activities of JNK and
p38 were determined by their ability to phosphorylate the
substrates c-Jun and ATF-2, respectively. The kinetics of
JNK activation were distinct from that of ERK2, being
marked at 10 min and being declined by 30 min. The ac-
tivation of p38 was maximal at 3 and 10 min, and more
sustained than that of JNK (Figs. 4 and 6). Contrary to
ERK2 activation, expression of RasN17 did not signifi-
cantly affect the JNK and p38 responses upon BCR en-
gagement (Fig. 6). Consistent with these observations,
Grb2-deficient DT40 cells also showed normal JNK and
p38 responses (data not shown). These findings prompted
us to examine the involvement of Rac1 in BCR-induced
JNK and p38 activation, since recent experiments in fibro-
blasts have shown that Rac1, rather than Ras, is an efficient
activator of a cascade leading to JNK and p38 activation
(18–20). Expression of Rac1N17 in DT40 cells (Fig. 1 C)
markedly inhibited both JNK and p38 activation after
BCR cross-linking (Fig. 6), whereas ERK2 activation was
not affected (data not shown). These results indicate that
Rac1 but not Ras is required for JNK and p38 activation
after BCR ligation.
PLC-g2–dependent Signaling Is Required for JNK and p38
Activation. A calcium ionophore has been shown to acti-
vate JNK in B cells (16, 35). This suggests that other activa-
tors of JNK, such as ligated BCR, may use [Ca21]i increase
for maximum JNK activation. Likewise, p38 response also
might be dependent on the [Ca21]i increase in B cells. To test
these possibilities, we examined the BCR-induced activation
of JNK and p38 in PLC-g2– and IP3R-deficient DT40 cells.
As shown in Fig. 7, both PLC-g2– and IP3R-deficient DT40
cells exhibited impaired JNK responses, suggesting the de-
pendency of the JNK response on the calcium pathway rather
than the PKC pathway. However, a residual JNK response
was still observed even in the IP3R-deficient DT40 cells.
Activation of p38 upon BCR engagement was com-
pletely abolished by loss of PLC-g2, whereas this response
was still observed in IP3R-deficient DT40 cells (Fig. 7).
These results suggest that the BCR-induced p38 response
requires a dominantly PKC pathway.
Discussion
In this study, we have addressed three questions regard-
ing the regulation of ERK, JNK, and p38 by BCR, poten-
tially leading to altered transcription of genes. First, are dis-
Figure 2. Cross-reactivity of various Abs. DT40 cell extracts were im-
munoprecipitated by anti-ERK2 Ab, anti-p38 Ab, and anti-JNK Ab.
These immunoprecipitates were separated by 9% SDS-PAGE gels, trans-
ferred to nitrocellulose membranes, and incubated with indicated Abs
(Blot Ab).
Figure 3.  BCR-induced
ERK2 activation in various
DT40 cells. Various DT40 cells
were stimulated with M4 (4 mg/
ml) for indicated time. ERK2
was immunoprecipitated and
the precipitates were assayed for
kinase activity using GST–Elk1
fusion protein as a substrate. The
kinase reaction products were re-
solved by 12.5% SDS-PAGE and
their phosphorylation was quan-
tified by autoradiography.
Figure 4. Time kinetics of
ERK2, JNK, and p38 responses
upon BCR engagement. After
BCR stimulation, DT40 cell ly-
sates were immunoprecipitated
with anti-ERK2 Ab, anti-JNK1
Ab, or anti-p38 Ab. The kinase
activities were assayed using
GST–Elk1, GST–c-Jun, and
GST–ATF2 as substrates for
ERK2, JNK, and p38, respec-
tively.1291 Hashimoto et al.
tinct GTPases required for the BCR-induced ERK, JNK,
and p38 responses? Second, particularly in the ERK re-
sponse, is either Grb2 or Shc, or both of them, essential for
this response? Third, are GTPases the sole regulators of
BCR-induced activation of these MAP kinase family
members?
Since the two SH3 domains of Grb2 bind to proline-rich
residues near the COOH terminus of Sos, Grb2 is thought
to mediate the translocation of Sos to the plasma mem-
brane, allowing Sos to activate membrane-bound Ras. In
the case of the epidermal growth factor (EGF) receptor,
translocation of Grb2 to membrane can occur upon bind-
ing of its SH2 domain to the autophosphorylated tail of the
EGF receptor (36–40). However, because the BCR com-
plex does not possess Grb2 binding sites despite activating
Ras, an alternate model for Ras activation has been pro-
posed. According to this model, BCR ligation leads to the
recruitment of Shc to the plasma membrane, whereupon it
undergoes tyrosine phosphorylation of the Grb2 binding
site, thereby recruiting Grb2 to the plasma membrane (38).
Indeed, BCR stimulation leads to tyrosine phosphorylation
of Shc and to the assembly of an Shc–Grb2–Sos complex
(8, 41–43). However, the data presented here indicate that
Grb2 but not Shc is required for BCR-induced ERK re-
sponse. These findings indicate the dispensability of Shc in
Ras activation in BCR signaling, and raise the previous
question of how Grb2 is recruited to the plasma membrane
after BCR ligation. One candidate adaptor molecule might
be LAT, an integral membrane protein that is phosphory-
lated and bound to Grb2 (44). Although LAT is expressed
predominantly in T cells, B cells might express a similar
molecule that is required for Grb2 recruitment to the
membrane. This candidate molecule is tyrosine phosphory-
lated presumably by Syk, since the accompanying study has
shown that Syk, but not Lyn, is a responsible kinase for
BCR-induced ERK activation (32).
The extent of inhibition by RasN17 of BCR-mediated
ERK2 activation was almost the same level as that observed
in Grb2-deficient DT40 cells, suggesting that the Grb2-defi-
cient phenotype in BCR signaling can be accounted for by
loss of Ras activation. In contrast to the almost complete
inhibition of EGF receptor–induced ERK response by ex-
pression of RasN17 (45), we observed residual BCR-induced
ERK2 activation despite loss of Grb2 or expression of Ras
N17. These observations provide important implications.
First, the sensitivity to requirement of Ras for ERK activa-
tion might vary depending on receptor systems. In this re-
gard, TCR-induced ERK response appears to be more
strictly dependent on Ras activation than is BCR (46). Sec-
ond, the BCR uses an additional signaling pathway to stim-
ulate ERK even in the absence of Ras activation, and
probably this additional signaling pathway, in addition to
Ras, is required for maximum BCR-induced ERK activa-
tion. This additional signal is provided by PKC activation,
since PLC-g2–deficient DT40 cells, but not IP3R-defi-
cient, exhibited profound loss in ERK2 activation by BCR
ligation. Furthermore, expression of RasN17 in PLC-g2–
deficient cells led to the complete abrogation of BCR-
induced ERK2 activation, suggesting the synergistic action
of Ras and the PKC pathway for BCR-induced ERK acti-
Figure 5. Involvement of PLC-g2 and Ras on BCR-induced ERK2
activation. BCR-stimulated DT40 cells were lysed and immunoprecipi-
tated with anti-ERK2 Ab. Stimulation conditions and in vitro kinase as-
say were described as in Fig. 3.
Figure 6. Effect of RasN17 and Rac1N17 on JNK and p38 responses.
DT40 cells were stimulated with M4 (4 mg/ml) for indicated times. Cell
lysates were immunoprecipitated with anti-JNK1 Ab and anti-p38 Ab,
and kinase activities were assayed using GST–c-Jun and GST–ATF2 as
substrates, respectively. After electrophoresis, the labeled GST–c-Jun and
GST–ATF2 bands were visualized by autoradiography.1292 Activation of MAP Kinase Family Members by PLC-g2 and GTPases
vation. As we have recently shown that PKC activation
is negatively regulated by Lyn in B cells (47), the exagger-
ated activation of ERK in lyn2/2 mice (48) might be ex-
plained by the enhanced activation of the PKC-dependent
pathway.
In contrast to the ERK response, the JNK and p38 re-
sponses are not affected by expression of RasN17. Con-
versely expression of Rac1N17 abolished the JNK and p38
activation without affecting the ERK response in B cells.
This difference presumably reflects that distinct exchange
factors, Sos and Vav, participate in ERK and JNK/p38 re-
sponses through activating Ras and Rac1, respectively, in
BCR signaling. Supporting this notion, recent experiments
have shown that Vav, upon tyrosine phosphorylation, stim-
ulates Rac1 (21–23). Our results reveal that not only Rac1-
but also PLC-g2–dependent signal is required for BCR-
induced JNK/p38 response; JNK is dependent on calcium
mobilization rather than PKC activation, whereas p38 re-
quires the PKC pathway. Requirement of calcium for JNK
activation agrees with the data that JNK response, but not
p38 response, is inhibited by treatment of BAPTA-AM, a
chelator of both intracellular and extracellular calcium (32).
The requirement of both Rac1 and PLC-g for JNK activa-
tion is well conserved between B and T cells. Indeed, the
data presented in this study and the accompanying paper
(32) are consistent with the findings that JNK activation in
T cells requires calcium-dependent calcineurin and Syk, in
addition to Rac1 (49, 50).
Although this study has not addressed the mechanism by
which PKC and calcium regulate p38 and JNK activation
by BCR, modulation of the signaling pathway upstream of
Rac1 by PKC and calcium seems to be unlikely, as Vav be-
haves as a tyrosine phosphorylation–dependent exchange
factor for Rac1 (21–23). Rather, distinct requirement for
PKC and calcium for p38 and JNK, respectively, might
suggest that downstream molecules of Rac1 are potential
targets of PKC and calcium. Analogous to Raf, which is re-
cruited by Ras (51), and which is a substrate of PKC (52),
another kinase participating in the cascade leading to p38
and JNK response might be a substrate of PKC and a cal-
cium-dependent kinase, respectively.
Regulation of ERK, JNK, and p38 by PKC and calcium
might provide insights into the mechanism by which
CD19 costimulates the activation of these MAP kinase
family members by BCR. Although coclustering CD19
and BCR leads to enhanced activation of ERK, the CD19-
mediated enhancement of JNK and p38 responses is more
dramatic (53). Since CD19 associates with Vav and phos-
phatidylinositol 3 kinase (54–57), coligation of CD19 with
BCR brings these molecules into the close proximity of the
BCR signaling complex. This may lead to further enhance-
ment of tyrosine phosphorylation of Vav by Lyn and Syk,
leading to its enhanced activation towards Rac1. Recently,
phosphatidylinositol 3 kinase has been reported to partici-
pate in the enhanced calcium mobilization (58–60), which
potentially could lead to augmented JNK activation. Con-
versely, inhibitory receptors such as PIR-B and FcgRIIB
on B cells are predicted to inhibit these MAP kinase family
members, as these receptors downregulate the BCR-induced
PLC-g2 activation and calcium mobilization (61–63).
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